a slight trendp = 0.08
APBI showed a slight trend of lower toxicity with 5‐year risk of grade 2–3 late side effects to the skin being 3.2% with APBI vs. 5.7% with CF‐WBI ( p = 0.08), and both with very low 5‐year risk of grade 2–3 subcutaneous fibrosis. 46 Therefore, the trial established equivalency between postoperative APBI using multicatheter brachytherapy and postoperative CF‐WBI for patients with early breast cancer in terms of local control, disease‐free survival, and OS. 2.4.4.